This three-receptor profile makes it a reference compound for multi-agonist receptor pharmacology
His current strategy is a long-term pivot focused on building a new revenue base for 2030 through major acquisitions and cost-cutting, rather than chasing short-term gains with buybacks
While injectable glutathione provides exogenous glutathione directly, concurrent NAC supplementation supports the body's endogenous glutathione production capacity
The catch and this is where honesty matters on a YMYL page is that can survive the gut in principle is not the same as has a proven, quantified oral bioavailability in humans. No such human number exists for this molecule
Frias JP, Auerbach P, Bajaj HS et al
Stated by Lilly: Q1 2027 (announced July 23, 2026, superseding the "submit in 2026" guidance given on the Q4 2025 earnings call, February 4, 2026)